Featured Articles

  • Logic-gated CAR-T

    Wednesday, July 08, 2026
    As logic-gated CAR-Ts advance into human studies, the field is moving toward multi-layered platforms that integrate Boolean logic, microenvironmental sensing, enhanced trafficking, and dynamic control of T-cell behavior, with the goal of ... read more

  • Cell therapy’s real cost problem starts in the culture flask

    Monday, June 29, 2026
    Some of the most actionable levers may sit earlier in the process than the industry has been looking. read more

  • Avoiding CMC pitfalls

    Tuesday, June 23, 2026
    A clear CMC roadmap is critical as global regulators expect to see not only a snapshot of current controls but a clear path showing how a process will mature and scale throughout development and commercialization. read more

  • Refining the molecular blueprint of in vivo CAR-T

    Thursday, June 18, 2026
    Laboratory management software can’t build a perfectly optimized construct for an in vivo CAR-T cell therapy, but it can make the lives of the scientists doing so considerably easier. read more

  • Placenta as the missing link

    Monday, June 15, 2026
    When you combine an ethical, plentiful human tissue source with disciplined manufacturing and true codevelopment partnerships, you get a realistic way to scale human-derived biomaterials. read more

  • All the CAR-T in China

    Wednesday, June 10, 2026
    The real risk is not that one country pulls ahead. It’s that friction — political, regulatory or economic — slows the system as a whole. read more

  • Cell and gene therapy takeaways from ASCO 2026

    Wednesday, June 03, 2026
    The American Society for Clinical Oncology annual meeting never fails to deliver inspiring advances in cancer-care. read more

  • Coexistence, not conflict, in cell therapy platform war

    Wednesday, May 27, 2026
    In theory, in vivo makes other cell therapies obsolete, but a panel at BPI Europe in Vienna last month painted a more measured picture. read more

  • Ten best practices for developing ophthalmic CGTs

    Wednesday, May 20, 2026
    Here are 10 best practices that can help drug developers avoid delays, protect data quality, and meet regulatory, clinical and manufacturing expectations. read more

  • Make drugs, not war

    Friday, May 08, 2026
    Developers who treat China’s rise as a strategic opportunity — both for partnership and as a wakeup call to address inefficiencies in Western systems — will be best positioned to take home the ultimate prize: bringing lifesaving treatments ... read more

  • Container closure integrity in the deep cold

    Wednesday, April 29, 2026
    Robust CCI verification is essential not only for regulatory compliance but also for protecting product stability and patient safety. As advanced therapies become more complex, the rigor and precision of CCI testing will remain ... read more

  • Visible particulates in cell therapy

    Wednesday, April 15, 2026
    The cell therapy sector remains constrained by particulate guidance based on traditional parenteral products, says a BioPhorum publication. read more
Page